Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Radiology
•
Inflammatory arthritis
•
Nuclear Medicine
When would you consider utilizing bone scintigraphy in the assessment of inflammatory arthritis?
Answer from: at Community Practice
When it's a case of negative RA disease or when considering a neoplastic, gammopathy with myeloma...
Sign In
or
Register
to read more
Answer from: at Community Practice
I would also consider using triple phase bone scan to assess the blood pool phase which may help determine sites of active inflammation. This may also help guide sites for intervention/injection.
Sign In
or
Register
to read more
14606
22338
Related Questions
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
When screening for malignancy, do you order CT with contrast (or) both with and without contrast?
What is the interpretation of an IGRA with positive TB wells and negative nil and negative mitogen wells?
How do you approach diagnosis in a patient with inflammatory joint symptoms and isolated bilateral CMC joint erosions on x-ray imaging?
Do you have safety concerns when prescribing GLP-1 medications in patients on corticosteroids or immunosuppressive therapy?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
What is the recommended fungal workup in an immunocompromised patient after 5 days of persistent fever?